Naltrexone in the treatment of dissociative symptoms in patients with borderline personality disorder: An open-label trial

Journal of Clinical Psychiatry

Volumn 60, Issue 9, 1999, Pages 598-603

  Bohus, Martin J ^a   Landwehrmeyer, G Bernhard ^a   Stiglmayr, Christian E ^a   Limberger, Matthias F ^a   Böhme, Renate ^a   Schmahl, Christian G ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

NALOXONE; NALTREXONE;

ADOLESCENT; ADULT; ARTICLE; BORDERLINE STATE; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; HYSTERIA; MENTAL DISEASE; PERSONALITY DISORDER; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; RATING SCALE; SYMPTOMATOLOGY;

EID: 0032872355     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v60n0906     Document Type: Article

References (31)

1. Weissman MM. The epidemiology of personality disorders: a 1990 update. J Personal Disord 1993;7(suppl spring):44-62
2. Widiger TA, Frances AJ. Epidemiology, diagnosis and comorbidity of borderline personality disorder. In: Tasman A, Hales RE, Frances AJ, eds. Review of Psychiatry, vol. 8. Washington, DC: American Psychiatric Press; 1989:8-24
3. Zanarini MC. Evolving perspectives on the etiology of borderline personality disorder. In: Zanarini MC, ed. Role of Sexual Abuse in the Etiology of Borderline Personality Disorder. Progress in Psychiatry, No. 49. Washington, DC: American Psychiatric Press Inc; 1997:1-14
4. Millon TM, Davis RD. Personality theories: historical, modern, and contemporary. In: Millon TM, Davis RD, eds. Disorders of Personality DSM-IV and Beyond. New York, NY: John Wiley & Sons; 1996:35-80
5. Zanarini MC, Gunderson JG, Frankenburg FR. Cognitive features of borderline personality disorder. Am J Psychiatry 1990;147:57-63
6. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
7. Krystal JH, Bennett AL, Bremner JD, et al. Toward a cognitive neuroscience of dissociation and altered memory functions in post-traumatic stress disorder. In: Friedman MJ, Charney DS, Deutsch AY, eds. Neurobiological and Clinical Consequences of Stress. Philadelphia, Pa: Lippincott-Raven Publishers; 1995:238-269
8. Le Doux JE. Information flow from sensation to emotion: plasticity in the neural computation of stimulus value. In: Gabriel M, Moore J, eds. Learning and Computational Neuroscience. Cambridge, Mass: Bradford Books/ MIT Press; 1990:3-51
9. Russ MJ, Roth SD, Lerman A, et al. Pain perception in self-injurious patients with borderline personality disorder. Biol Psychiatry 1992;32: 501-511
10. Noyes R. Depersonalization in response to life-threatening danger. Psychiatry 1977;18:375-384
11. Chu JA, Dill DL. Dissociative symptoms in relation to childhood physical and sexual abuse. Am J Psychiatry 1990;147:887-892
12. Terman GW, Shavit Y, Lewis JW, et al. Intrinsic mechanisms of pain inhibition: activation by stress. Science 1984;226:1270-1277
13. van der Kolk BA, Greenberg MS, Orr SP, et al. Endogenous opioids, stress induced analgesia, and post-traumatic stress disorder. Psychopharmacol Bull 1989;25:417-425
14. Pitman RK, van der Kolk BA, Orr SP, et al. Naloxone-reversible analgesic response to combat-related stimuli in post traumatic stress disorder. Arch Gen Psychiatry 1990;47:541-544
15. Winchel RM, Stanley M. Self-injurious behavior a review of the behavior and biology of self-mutilation. Am J Psychiatry 1991;148:306-317
16. Sonne S, Rubey R, Brady K, et al. Naltrexone treatment of self-injurious thoughts and behaviors. J Nerv Ment Dis 1996;184:192-195
17. Bills LJ, Kreisler K. Treatment of flashbacks with naltrexone [letter]. Am J Psychiatry 1993;150:1430
18. Gunderson JG, Kolb JE, Austin Y. The Diagnostic Interview for Borderline Patients. J Pers Soc Psychol 1981;138:896-903
19. Linehan MM. Cognitive Behavioral Treatment of Borderline Personality Disorder. New York, NY: Guilford Press; 1993
20. Bernstein EM, Putnam FW. Development, reliability and validity of a dissociation scale. J Nerv Ment Dis 1986;174:727-735
21. Freyberger HJ, Spitzer C, Stieglitz RD. Fragebogen zu dissoziativen Symptomen (FDS). Deutsche Adaptation der Dissociative Experience Scale (DES). Bern, Switzerland: Verlag Hans Huber; 1998
22. Nijenhuis ERS, Spinhoven P, van Dyck R, et al. The development and psychometric characteristics of the Somatoform Dissociation Questionnaire (SDQ-20). J Nerv Ment Dis 1996;184:688-694
23. Dhawan BN, Cesselin F, Raghubir R, et al. International Union of Pharmacology, XII: classification of opioid receptors. Pharmacol Rev 1996;48: 567-592
24. Berg BJ. A risk-benefit assessment of naltrexone in the treatment of alcohol dependence. Drug Saf 1996;15:274-282
25. Coid J, Allolio B, Rees LH. Raised plasma metenkephalin in patients who habitually mutilate themselves. Lancet 1983;2:545-546
26. Pickar D, Cohen MR, Naber D, et al. Clinical studies of the endogenous opioid system. Biol Psychiatry 1982;17:1243-1276
27. Wolf ME, Mosnaim AD, Puente J, et al. Plasma methionine enkephalin in PTSD. Biol Psychiatry 1991;29:305-307
28. Hoffman L, Watson PB, Wilson G, et al. Low plasma beta-endorphin in post-traumatic stress disorder. Aust NZJ Psychiatry 1989;23:268-273
29. Kumor KM, Haertzen CA, Johnson RE, et al. Human psychopharmacology of ketocyclazocine as compared with cyclazocine, morphine and placebo. J Pharmacol Exp Ther 1986;238:960-968
30. Pfeiffer A, Brantl V, Herz A, et al. Psychotomimesis mediated by κ opiate receptors. Science 1986;233:774-776
31. Roth AS, Ostroff RB, Hoffman RE. Naltrexone as a treatment for repetitive self-injurious behavior: an open-label trial. J Clin Psychiatry 1996;57: 233-237